
|Articles|April 28, 2023
Trends in Bio/Pharma Facilities: Ken Gilmartin Gives His Perspective (INTERPHEX 2023)
Wood CEO Ken Gilmartin gives his insight on what's currently in demand in terms of new bio/pharma manufacturing facilities.
Advertisement
Ken Gilmartin, CEO, Wood, gives his insight on what's currently in demand in terms of new bio/pharma manufacturing facilities. He emphasizes that a significant amount of capital is being invested in the United States for facilities, particularly in the large molecule and cell and gene therapy sectors.
For more INTERPHEX 2023 video content, check
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies
2
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
3
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
4
Next-Generation Modalities Drive New Antibody Discovery
5




